Select Page

How does EVQLV’s technology work?

Jun 1, 2020 | Blog | 0 comments

Daniel Gigante

This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video).


We use nearly a hundred billion data points across a wide range of biological data. That includes gene sequences, biological structures, biophysical properties and more. And we integrate all that data and then apply our evolutionary algorithms and computational tests. This all gives our artificial intelligence engine the ability to make statistically informed decisions.

To be clear, this process is not about replacing the work of scientists in the lab. Instead, it’s about accelerating and augmenting the decision-making being made by life scientists as they work on drugs for the coronavirus.

We’re driven, at our company, to use computational technology to support each key member in the drug discovery and development process, in order to prevent failure in the lab, in animal tests, or in clinical trials.

Today, our technology works by taking an existing antibody sequence. For example, an antibody that targets the spike of the coronavirus that may have come from an animal or a patient that recovered from the coronavirus. We then apply our proprietary evolutionary algorithms to generate evolutionary mutated daughters of those antibodies. By taking those antibodies that we know target the coronavirus and applying our algorithms, we can generate variants that could be used in larger segments of the population.


Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...